{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:34:41Z","timestamp":1778934881552,"version":"3.51.4"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,2,25]]},"abstract":"<jats:p>Acute interstitial nephritis (AIN) has a number of medication-related aetiologies. Antibiotics, proton pump inhibitors and non-steroidal anti-inflammatory drugs are common causes; however, any medication has the potential to cause drug-induced AIN. We report the first case of phentermine-induced AIN. A Caucasian woman aged 43 years presented with a 5-week history of lethargy, left-sided lower abdominal pain, nausea and vomiting. She had been taking phentermine for weight loss for 9\u2005months and had recently ceased the medication. The patient underwent a renal biopsy that showed a predominantly lymphohistiocytic interstitial infiltrate with a moderate number of eosinophils consistent with AIN. Phentermine is increasingly used for weight loss in obese patients. This is the first case implicating phentermine as the causative agent for drug-induced AIN. While rare, phentermine-induced AIN is a possible adverse reaction of phentermine. Physicians and patients need to be aware of this risk.<\/jats:p>","DOI":"10.1136\/bcr-2017-219452","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T15:35:39Z","timestamp":1489073739000},"page":"bcr2017219452","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Phentermine induced acute interstitial nephritis"],"prefix":"10.1136","volume":"2017","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-7109","authenticated-orcid":false,"given":"Emily Ximin","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory John","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwarakanathan","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.027"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.294"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs143"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/phar.1342","article-title":"Use of prescription antiobesity drugs in the United States","volume":"33","author":"Hampp","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.5","first-page":"252","article-title":"Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine","volume":"50","author":"Markowitz","year":"1998","journal-title":"Clin Nephrol"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00007611-198402000-00035","article-title":"Amphetamine-induced acute renal failure","volume":"77","author":"Foley","year":"1984","journal-title":"South Med J"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.7","first-page":"214","article-title":"Methamphetamine and the expanding complications of amphetamines","volume":"170","author":"Albertson","year":"1999","journal-title":"West J Med"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7196\/SAMJ.8731","article-title":"Hypertension, end-stage renal disease and mesangiocapillary glomerulonephritis in methamphetamine users","volume":"105","author":"Jones","year":"2015","journal-title":"S Afr Med J"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.71"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh485"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.11","first-page":"179","article-title":"The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis","volume":"54","author":"Schwarz","year":"2000","journal-title":"Clin Nephrol"},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.12","unstructured":"FDA. Phentermine label at FDA. 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/085128s065lbl.pdf ."},{"key":"2025042705364823000_2017.mar09_1.bcr2017219452.13","unstructured":"TGA. METERMINE(Phentermine) Product Information: TGA. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-06558-3&d=2016111916114622483 ."}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-219452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:36:55Z","timestamp":1745757415000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-219452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":13,"alternative-id":["10.1136\/bcr-2017-219452"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-219452","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}